Baxter International (NYSE:BAX) Issues Earnings Results, Beats Expectations By $0.19 EPS

Baxter International (NYSE:BAX) posted its earnings results on Thursday. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19, FiscalAI reports. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. Baxter International updated its FY 2026 guidance to 1.950-2.150 EPS.

Here are the key takeaways from Baxter International’s conference call:

• Second-quarter sales rose 5% organically to approximately $3 billion, with growth across all segments and geographies. Advanced Surgery and drug compounding were standout contributors, while hospital demand and order books remained solid.
• Baxter raised its 2026 organic sales-growth outlook to 2%-3% and adjusted EPS guidance to $1.95-$2.15 per share, helped by stronger year-to-date performance and a $75 million tariff refund.
• Adjusted EPS declined 5% to $0.56, reflecting higher-cost inventory, an unfavorable prior-year accounting comparison, and mix pressure from fast-growing but lower-margin drug compounding. Management expects operating margins to improve in the second half as these headwinds roll off and cost actions take effect.
• The Novum IQ LVP infusion pump remains subject to a shipment and installation hold while Baxter conducts verification testing and works with regulators. Injectable sales and parts of the pharmaceutical portfolio also remain constrained by supply issues, including problems at a contract manufacturer.
• Second-quarter free cash flow reached $181 million, bringing year-to-date free cash flow to $257 million. Management is increasingly confident it can reduce net leverage to approximately 3x by year-end, potentially creating capacity for tuck-in acquisitions or share repurchases.

Baxter International Trading Up 7.6%

Shares of Baxter International stock traded up $1.88 during mid-day trading on Thursday, hitting $26.65. 22,670,769 shares of the stock were exchanged, compared to its average volume of 8,385,931. Baxter International has a twelve month low of $15.73 and a twelve month high of $30.00. The stock has a market capitalization of $13.76 billion, a price-to-earnings ratio of -12.51, a price-to-earnings-growth ratio of 3.93 and a beta of 0.62. The company has a 50-day simple moving average of $21.05 and a 200 day simple moving average of $19.52. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Barclays increased their price target on shares of Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Weiss Ratings upgraded Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. UBS Group upped their target price on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday. The Goldman Sachs Group increased their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Stifel Nicolaus raised their price target on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $21.09.

Key Headlines Impacting Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Quarterly earnings and revenue beat expectations. Baxter reported adjusted EPS of $0.56, versus the $0.36–$0.37 analyst consensus, while sales reached approximately $2.96 billion compared with estimates near $2.80 billion. Revenue grew 5.3% year over year, supported by broad-based segment growth. Baxter raises annual profit forecast on strong demand for IV solutions
• Positive Sentiment: Management raised its 2026 guidance. Full-year adjusted EPS guidance increased to $1.95–$2.15 from the prior $1.85–$2.05 range, above consensus of about $1.92. Revenue guidance was set at $11.6–$11.7 billion, also exceeding the roughly $11.4 billion consensus. The company said an unanticipated tariff refund provided an additional benefit. Baxter Reports Second-Quarter 2026 Results
• Positive Sentiment: Investor confidence in the turnaround improved. Coverage highlighted robust demand for IV solutions and progress in Baxter’s operational recovery. UBS also raised its price target to $25, adding to recent target increases from Stifel and TD Cowen. Baxter shares jump after beat and raise

Hedge Funds Weigh In On Baxter International

Several institutional investors and hedge funds have recently modified their holdings of the company. Imprint Wealth LLC acquired a new stake in Baxter International during the third quarter worth approximately $27,000. MUFG Securities EMEA plc purchased a new stake in Baxter International in the 2nd quarter worth approximately $46,000. Los Angeles Capital Management LLC acquired a new position in Baxter International in the 4th quarter valued at $46,000. McMillan Office Inc. acquired a new position in Baxter International in the 4th quarter valued at $54,000. Finally, Parallel Advisors LLC lifted its stake in shares of Baxter International by 113.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,971 shares of the medical instruments supplier’s stock worth $90,000 after purchasing an additional 2,109 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.